GlassScriptPhysician profile
Sara D Schalk
NPI 1275617300
$3,896.14
in general payments reported to CMS, 2019-2025
24 companies · $704 in 2025
The $704 reported for 2025 was more than what 85% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $387 · 2020: $404 · 2021: $751 · 2022: $515 · 2023: $638 · 2024: $496 · 2025: $704.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,750 · Education: $87.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,750.32 |
| Education | $87.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $507.36 | 2019-2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $451.35 | 2019-2021 | |
| Allergan, INC. | $436.76 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $434.70 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Mallinckrodt Hospital Products INC. | $319.34 | 2024-2025 | Acthar |
| Sun Pharmaceutical Industries INC. | $249.49 | 2019-2025 | Cequa |
| Kala Pharmaceuticals, INC. | $236.24 | 2020-2022 | |
| Oyster Point Pharma, INC. | $205.89 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Dompe US, INC. | $136.63 | 2022-2025 | Oxervate |
| Abbvie INC. | $134.96 | 2023-2025 | Alphagan P, Lumigan, Vuity |
| Regeneron Healthcare Solutions, INC. | $132.50 | 2019-2025 | Eylea Hd, Eylea |
| Horizon Therapeutics Plc | $126.93 | 2021-2023 | Tepezza |
| Alcon Vision LLC | $109.40 | 2022-2025 | Tryptyr, Hydrus Microstent |
| Astellas Pharma US INC | $101.28 | 2023-2025 | Izervay |
| Amgen INC. | $74.65 | 2024 | Tepezza |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $42.24 | 2019 | |
| Apellis Pharmaceuticals, INC. | $34.03 | 2023 | Syfovre |
| Coopervision INC. | $33.10 | 2019-2024 | Myday Contact Lens |
| Thea Pharma INC. | $30.71 | 2025 | Iyuzeh |
| Tarsus Pharmaceuticals, INC. | $28.90 | 2024 | Xdemvy |
| Glaukos Corporation | $21.86 | 2024 | Ce-Marked Kxla System |
| Biotissue Holdings INC. | $19.76 | 2023 | |
| Rxsight INC | $14.55 | 2022 | |
| Harrow Eye, LLC | $13.51 | 2025 | Iheezo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Schalk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.